NASDAQ:LENS Presbia (LENS) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free LENS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.07▼$0.3252-Week Range N/AVolumeN/AAverage Volume122,366 shsMarket Capitalization$258,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Presbia alerts: Email Address Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Presbia Stock (NASDAQ:LENS)Presbia PLC is a holding company. It engages in the development and marketing of presbyopia-correcting solutions under the trademark of Presbia Flexivue Microlens. It operates through the Restoration of Clear Vision Caused by Presbyopia segment. The company was founded on February 2, 2014 and is headquartered in Dublin, Ireland.Read More Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. LENS Stock News HeadlinesFebruary 7, 2024 | forbes.com12 Of The Best Contact Lenses, According To An OphthalmologistFebruary 1, 2024 | time.comContact Lens King CouponsApril 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.January 16, 2024 | bbc.co.ukReal and virtual imagesApril 29, 2023 | forbes.comIf You Want To Wear Colored Contact Lenses, FDA Has A WarningMarch 31, 2023 | cnet.comNever Do These 13 Things With Contact LensesMarch 20, 2023 | bbc.co.ukTypes of lensMarch 16, 2023 | bbc.co.ukConvex and concave lensesApril 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.February 24, 2023 | dailymail.co.ukI fell asleep with contact lenses in and a flesh-eating bug ate my EYEFebruary 17, 2023 | techcrunch.comSnap introduces ray tracing technology for its AR lenses to enhance realismJanuary 6, 2023 | finance.yahoo.comCCTV Lens Market valued at 1.5 Billion in 2022, is set to witness a growth of 8.93% in the next 7 yearsOctober 15, 2022 | dailymail.co.ukWorld's largest camera with a five-foot-wide lens powerful enough to spot a golf ball from 15 miles away is unveiled by astronomers - and will be used to capture the night sky ...September 25, 2022 | thetimes.co.ukReusable contact lenses ‘raise risk of eye infection’September 25, 2022 | nypost.comReusable contact lenses could cause blindness: studyMay 4, 2022 | yahoo.comCorneal Implants Market to hit USD 495 Million by 2028, Says Global Market Insights Inc.November 13, 2021 | marketwatch.comPresbyopia Correction Devices Market Report Leading Companies, Spotting Market Dynamics and Business Opportunities 2022 to 2027See More Headlines Receive LENS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Presbia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2016Today4/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolNASDAQ:LENS CUSIPN/A CIK1591096 Webwww.presbia.com Phone(531) 551-1487FaxN/AEmployees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,410,000.00 Net Margins-36,604.35% Pretax MarginN/A Return on Equity-414.02% Return on Assets-195.56% Debt Debt-to-Equity Ratio1.24 Current Ratio2.88 Quick Ratio2.82 Sales & Book Value Annual Sales$20,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / BookN/AMiscellaneous Outstanding Shares17,230,000Free FloatN/AMarket Cap$258,000.00 OptionableNot Optionable Beta2.57 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesZohar LoshitzerExecutive Chairman & Chief Executive OfficerCasey LindChief Operating OfficerKey CompetitorsMotus GINASDAQ:MOTSSintx TechnologiesNASDAQ:SINTAthersysNASDAQ:ATHXBetter TherapeuticsNASDAQ:BTTXAptevo TherapeuticsNASDAQ:APVOView All Competitors LENS Stock Analysis - Frequently Asked Questions How were Presbia's earnings last quarter? Presbia PLC (NASDAQ:LENS) posted its quarterly earnings data on Friday, August, 12th. The medical instruments supplier reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.07. The medical instruments supplier had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.04 million. Presbia had a negative trailing twelve-month return on equity of 414.02% and a negative net margin of 36,604.35%. What other stocks do shareholders of Presbia own? Based on aggregate information from My MarketBeat watchlists, some companies that other Presbia investors own include Ritter Pharmaceuticals (RTTR), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA), Bellatrix Exploration (BXE), Second Sight Medical Products (EYES), Lilis Energy (LLEX), Marinus Pharmaceuticals (MRNS), Novavax (NVAX), Ampliphi Biosciences (APHB) and ArQule (ARQL). When did Presbia IPO? Presbia (LENS) raised $50 million in an initial public offering (IPO) on Thursday, January 29th 2015. The company issued 4,200,000 shares at a price of $11.00-$13.00 per share. Jefferies served as the underwriter for the IPO. This page (NASDAQ:LENS) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupHis win rate puts Warren Buffett to shame… Investing DailyTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Presbia PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
